RxDoctor Payments DataLook up a doctor →

Bobby Smith

Family · Albertville, ALNPI 1427556679

Payments from drug & device makers

$14,927in general payments, 2019–2025

Across 588 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$5K
  • AbbVie$3K
  • GSK$1K
  • Novartis$1K
  • AstraZeneca$820
  • Amgen$653
  • plus $3K from 23 others

What the payments were for

  • Consulting fees$3,30022%
  • Travel & lodging$6244%
  • Food & beverage$10,83073%
  • Education$1731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,927 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$27,241
Medicare patients
287
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab59$437,267
RinvoqUpadacitinib45$283,245
Enbrel SureclickEtanercept28$203,804
Xeljanz XrTofacitinib Citrate17$99,755
BenlystaBelimumab19$91,917
Orencia ClickjectAbatacept14$80,674
Actemra ActpenTocilizumab12$62,892
Hydroxychloroquine Sulfate471$49,972
ActemraTocilizumab30$44,517
Leflunomide97$11,649
MethotrexateMethotrexate Sodium237$8,698
Mycophenolate Mofetil52$6,363
Duloxetine Hcl102$3,239
Prednisone383$2,133
Febuxostat26$1,952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$3,318$283,24545 claims
GSKBenlysta$1,169$91,91719 claims
Scilex Pharmaceuticals Inc.Colchicine$53$71213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Albertville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →